Buscar
Ligand Pharmaceuticals Inc
LGNDAñadir a la lista de seguimiento
298.364USD
-2.166-0.72%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
5.90BCap. mercado
38.88P/E TTM
Más Datos de Ligand Pharmaceuticals Inc Compañía
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Información de Ligand Pharmaceuticals Inc
Símbolo de cotizaciónLGND
Nombre de la empresaLigand Pharmaceuticals Inc
Fecha de salida a bolsaNov 18, 1992
Director ejecutivoDavis (Todd C)
Número de empleados68
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 18
Dirección555 Heritage Drive, Suite 200
CiudadJUPITER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33458
Teléfono18585507500
Sitio Webhttps://www.ligand.com/
Símbolo de cotizaciónLGND
Fecha de salida a bolsaNov 18, 1992
Director ejecutivoDavis (Todd C)
Ejecutivos de Ligand Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
116.79K
-3.57%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
40.34K
+2.07%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
30.32K
--
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
27.37K
+0.06%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
10.14K
+8.25%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.19K
-26.25%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
5.54K
+11.79%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
--
--
Ms. Melanie J. Herman
Ms. Melanie J. Herman
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
116.79K
-3.57%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
40.34K
+2.07%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
30.32K
--
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
27.37K
+0.06%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
10.14K
+8.25%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.19K
-26.25%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Ligand Pharmaceuticals Inc?
Los cinco principales accionistas de Ligand Pharmaceuticals Inc son: Mr. Jason M. Aryeh
¿Cuántas instituciones poseen acciones de Ligand Pharmaceuticals Inc (LGND)?
A fecha de 2026Q1, 634 instituciones poseen acciones de Ligand Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 20.97M, lo que representa el 104.66% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -493867.00.
¿Cuál es la mayor fuente de ganancias de Ligand Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial Contract Revenue- Other generó la ganancia más alta para Ligand Pharmaceuticals Inc, ascendiendo a 66.87M y representando el 24.94% de la ganancia total.